COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia

Haruka Kaneko,1,2 Itaru Miura,1 Keiko Kanno-Nozaki,1 Sho Horikoshi,1 Mizuki Hino,1 Hirooki Yabe1 1Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan; 2Department of Neuropsychiatry, Hoshi General Hospital, Fukushima, Japan Introductio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kaneko H, Miura I, Kanno-Nozaki K, Horikoshi S, Hino M, Yabe H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	schizophrenia catechol-O-methyltransferase (COMT) Val 108/158 Met polymorphism (rs4680) aripiprazole pharmacogenetics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/279dd1eb058047d6a778565787b9d1f6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:279dd1eb058047d6a778565787b9d1f6
record_format	dspace
spelling	oai:doaj.org-article:279dd1eb058047d6a778565787b9d1f62021-12-02T04:21:57ZCOMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia1178-2021https://doaj.org/article/279dd1eb058047d6a778565787b9d1f62018-06-01T00:00:00Zhttps://www.dovepress.com/comt-val-108158-met-polymorphism-and-treatment-response-to-aripiprazol-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Haruka Kaneko,1,2 Itaru Miura,1 Keiko Kanno-Nozaki,1 Sho Horikoshi,1 Mizuki Hino,1 Hirooki Yabe1 1Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan; 2Department of Neuropsychiatry, Hoshi General Hospital, Fukushima, Japan Introduction: The COMT Val 108/158 Met polymorphism (rs4680) may affect treatment response to antipsychotics, as well as metabolism and dynamics of neurotransmitters during the treatment of schizophrenia. We investigated the effects of the COMT Val 108/158 Met polymorphism on treatment response to aripiprazole and plasma monoamine metabolite levels in patients with acute schizophrenia. Materials and methods: Forty patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured Positive and Negative Syndrome Scale (PANSS) and plasma levels of homovanillic acid (HVA) and plasma MHPG (3-methoxy-4-hydroxyphenethyleneglycol) at baseline and endpoint. The COMT Val 108/158 Met polymorphism was genotyped with the polymerase chain reaction and restriction fragment length polymorphism. Results: There were significant genotype–time interactions on PANSS total and general psychopathology scores, with Met/Met genotype showing greater improvement. The response rate to aripiprazole did not differ between COMT Val 108/158 Met genotype groups. We found a significant time effect on plasma MHPG levels, but no time effect on plasma HVA levels or time–genotype interactions in the plasma levels of HVA and MHPG. Although the responder rate did not differ among the 3 genotype groups. Conclusion: Our results suggest that individuals with the Met/Met genotype had greater improvement in PANSS score after the treatment with aripiprazole. On the other hand, the Val 108/158 Met polymorphism may not induce changes in plasma levels of monoamine metabolites during aripiprazole treatment. Because of the small sample size, further studies are needed to confirm and to extend our results. Keywords: schizophrenia, COMT, Val 108/158 Met polymorphism (rs4680), aripiprazole, pharmacogeneticsKaneko HMiura IKanno-Nozaki KHorikoshi SHino MYabe HDove Medical Pressarticleschizophreniacatechol-O-methyltransferase (COMT)Val 108/158 Met polymorphism (rs4680)aripiprazolepharmacogeneticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1657-1663 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia catechol-O-methyltransferase (COMT) Val 108/158 Met polymorphism (rs4680) aripiprazole pharmacogenetics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenia catechol-O-methyltransferase (COMT) Val 108/158 Met polymorphism (rs4680) aripiprazole pharmacogenetics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kaneko H Miura I Kanno-Nozaki K Horikoshi S Hino M Yabe H COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
description	Haruka Kaneko,1,2 Itaru Miura,1 Keiko Kanno-Nozaki,1 Sho Horikoshi,1 Mizuki Hino,1 Hirooki Yabe1 1Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan; 2Department of Neuropsychiatry, Hoshi General Hospital, Fukushima, Japan Introduction: The COMT Val 108/158 Met polymorphism (rs4680) may affect treatment response to antipsychotics, as well as metabolism and dynamics of neurotransmitters during the treatment of schizophrenia. We investigated the effects of the COMT Val 108/158 Met polymorphism on treatment response to aripiprazole and plasma monoamine metabolite levels in patients with acute schizophrenia. Materials and methods: Forty patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured Positive and Negative Syndrome Scale (PANSS) and plasma levels of homovanillic acid (HVA) and plasma MHPG (3-methoxy-4-hydroxyphenethyleneglycol) at baseline and endpoint. The COMT Val 108/158 Met polymorphism was genotyped with the polymerase chain reaction and restriction fragment length polymorphism. Results: There were significant genotype–time interactions on PANSS total and general psychopathology scores, with Met/Met genotype showing greater improvement. The response rate to aripiprazole did not differ between COMT Val 108/158 Met genotype groups. We found a significant time effect on plasma MHPG levels, but no time effect on plasma HVA levels or time–genotype interactions in the plasma levels of HVA and MHPG. Although the responder rate did not differ among the 3 genotype groups. Conclusion: Our results suggest that individuals with the Met/Met genotype had greater improvement in PANSS score after the treatment with aripiprazole. On the other hand, the Val 108/158 Met polymorphism may not induce changes in plasma levels of monoamine metabolites during aripiprazole treatment. Because of the small sample size, further studies are needed to confirm and to extend our results. Keywords: schizophrenia, COMT, Val 108/158 Met polymorphism (rs4680), aripiprazole, pharmacogenetics
format	article
author	Kaneko H Miura I Kanno-Nozaki K Horikoshi S Hino M Yabe H
author_facet	Kaneko H Miura I Kanno-Nozaki K Horikoshi S Hino M Yabe H
author_sort	Kaneko H
title	COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
title_short	COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
title_full	COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
title_fullStr	COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
title_full_unstemmed	COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
title_sort	comt val 108/158 met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/279dd1eb058047d6a778565787b9d1f6
work_keys_str_mv	AT kanekoh comtval108158metpolymorphismandtreatmentresponsetoaripiprazoleinpatientswithacuteschizophrenia AT miurai comtval108158metpolymorphismandtreatmentresponsetoaripiprazoleinpatientswithacuteschizophrenia AT kannonozakik comtval108158metpolymorphismandtreatmentresponsetoaripiprazoleinpatientswithacuteschizophrenia AT horikoshis comtval108158metpolymorphismandtreatmentresponsetoaripiprazoleinpatientswithacuteschizophrenia AT hinom comtval108158metpolymorphismandtreatmentresponsetoaripiprazoleinpatientswithacuteschizophrenia AT yabeh comtval108158metpolymorphismandtreatmentresponsetoaripiprazoleinpatientswithacuteschizophrenia
_version_	1718401298801360896

COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia

Ejemplares similares